文献速递神经肿瘤

Ⅱ/Ⅲ级胶质瘤微环境挖掘及其预后价值

Grade II/III Glioma Microenvironment Mining and Its Prognostic Merit.
PubMed 文献 · World Neurosurg · 2019-09-10

本研究利用ESTIMATE算法计算TCGAⅡ/Ⅲ级胶质瘤队列的基质/免疫评分,分析其与临床病理特征和总生存的关系,并通过功能富集和蛋白互作网络筛选关键预后基因,在CGGA数据中验证。结果显示高基质/免疫/ESTIMATE评分与不良生存显著相关,筛选出的7个差异基因在TCGA和CGGA中均显示预后价值。

要点

  • 高基质/免疫/ESTIMATE评分与Ⅱ/Ⅲ级胶质瘤患者不良生存显著相关。
  • 筛选出IL-10、B2M、CCL5、CD74、HLA-DRA、LCP2、MX1共7个预后相关差异基因。
  • 上述基因在TCGA和CGGA两个队列中均显示预后价值。

核心结论

  • 基质/免疫/ESTIMATE评分在Ⅱ/Ⅲ级胶质瘤患者中具有预后价值。
  • 筛选出的7个差异基因与肿瘤免疫和微环境相关,在Ⅱ/Ⅲ级胶质瘤中具有预后价值。

研究设计与样本

  • 研究从ESTIMATE在线门户获取TCGAⅡ/Ⅲ级胶质瘤队列的基质/免疫评分。
  • 采用Mann-Whitney U检验和Kaplan-Meier法分别评估评分与临床病理特征及总生存的关联。
  • 通过功能富集分析和蛋白互作网络分析差异表达基因,选取网络中边数≥5的前7个基因。
  • 利用CGGAⅡ/Ⅲ级胶质瘤数据进行验证。

主要发现

  • 升高的基质/免疫/ESTIMATE评分与TCGAⅡ/Ⅲ级胶质瘤患者不良生存显著相关。
  • 差异表达基因功能富集于免疫细胞调节、细胞外基质、细胞因子激活和受体结合。
  • 筛选的7个基因(IL-10、B2M、CCL5、CD74、HLA-DRA、LCP2、MX1)在TCGA和CGGAⅡ/Ⅲ级胶质瘤中均显示预后价值。

临床怎么用

  • 基质/免疫/ESTIMATE评分可用于Ⅱ/Ⅲ级胶质瘤的预后评估。
  • IL-10、B2M、CCL5、CD74、HLA-DRA、LCP2、MX1等基因可能作为预后标志物进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The tumor microenvironment greatly influences tumor formation, invasion, and progression. The ESTIMATE (Estimation of STromal and Immune cells in MAlignant Tumor tissues) algorithm quantifies stromal and immune components in a tumor, reflecting the tumor microenvironment. This study aimed to explore key prognostic genes in a grade II/III glioma microenvironment. METHODS: We obtained stromal/immune scores for the Cancer Genome Atlas (TCGA) grade II/III glioma cohort from the online ESTIMATE portal. The associations of stromal/immune scores with clinicopathologic characteristics and overall survival of patients with grade II/III glioma were assessed by the Mann-Whitney U test and the Kaplan-Meier method, respectively. Functional enrichment analysis and protein-protein interaction network assessments were employed to analyze differentially expressed genes (DEGs). The top 7 genes with 5 or more edges in the protein-protein interaction network were selected. For validation, CGGA grade II/III glioma data were analyzed. RESULTS: The results showed that elevated stromal/immune/ESTIMATE score was significantly associated with poor survival of patients with TCGA grade II/III glioma. Functional enrichment analysis showed that DEGs were associated with immune cell regulation, extracellular matrix, cytokine activation, and receptor binding. The selected DEGs (interleukin-10, beta-2 microglobulin, C-C motif chemokine ligand 5, cluster of differentiation 74, human leukocyte antigen-DRA, lymphocyte cytosolic protein 2, and myxovirus resistance protein 1) showed prognostic values in patients with grade II/III glioma of the TCGA and CGGA database. CONCLUSIONS: Stromal/immune/ESTIMATE scores have prognostic values in patients with grade II/III glioma. The selected DEGs, including interleukin-10, beta-2 microglobulin, C-C motif chemokine ligand 5, cluster of differentiation 74, human leukocyte antigen-DRA, lymphocyte cytosolic protein 2, and myxovirus resistance protein 1, associated with tumor immunity and microenvironment, have prognostic values in grade II/III glioma. Further investigation of these genes could provide novel insights into the tumor microenvironment of glioma.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Chen J, Hou C, Wang P, et al. Grade II/III Glioma Microenvironment Mining and Its Prognostic Merit. World Neurosurg. 2019. PMID: 31518750. doi:10.1016/j.wneu.2019.08.253

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。